Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containin

(E)-4-[3-(1-Adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) induces the cell-cycle arrest and apoptosis of leukemia and cancer cells. Studies demonstrated that 3-Cl-AHPC bound to the atypical orphan nuclear receptor small heterodimer partner (SHP). Although missing a DNA-binding domain, SHP heterodimerizes with the ligand-binding domains of other nuclear receptors to repress their abilities to induce or inhibit gene expression. 3-Cl-AHPC analogues having the 1-adamantyl and phenolic hydroxyl pharmacophoric elements replaced with isosteric groups were designed, synthesized, and evaluated for their inhibition of proliferation and induction of human cancer cell apoptosis. Structure-anticancer activity relationship studies indicated the importance of both groups to apoptotic activity. Docking of 3-Cl-AHPC and its analogues to an SHP computational model that was based on the crystal structure of ultraspiracle complexed with 1-stearoyl-2-palmitoylglycero-3-phosphoethanolamine suggested why these 3-Cl-AHPC groups could influence SHP activity. Inhibitory activity against Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp-2) was also assessed. The most active Shp-2 inhibitor was found to be the 3'-(3,3-dimethylbutynyl) analogue of 3-Cl-AHPC.

[1]  G. Giannini,et al.  Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. , 2007, Bioorganic & medicinal chemistry.

[2]  T. Kizaki,et al.  SHP-2 positively regulates adipogenic differentiation in 3T3-L1 cells. , 2007, International journal of molecular medicine.

[3]  T. Mustelin,et al.  An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity. , 2007, Journal of medicinal chemistry.

[4]  H. Mukhtar,et al.  SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG , 2007, Proceedings of the National Academy of Sciences.

[5]  M. Tartaglia,et al.  Structural and functional effects of disease‐causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP‐2 , 2006, Proteins.

[6]  Vincent Laudet,et al.  International Union of Pharmacology. LXVI. Orphan Nuclear Receptors , 2006, Pharmacological Reviews.

[7]  Grace Jones,et al.  The retinoid‐X receptor ortholog, ultraspiracle, binds with nanomolar affinity to an endogenous morphogenetic ligand , 2006, The FEBS journal.

[8]  E. McCabe,et al.  Dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome, gene 1 (DAX1) (NR0B1) and small heterodimer partner (SHP) (NR0B2) form homodimers individually, as well as DAX1-SHP heterodimers. , 2006, Molecular endocrinology.

[9]  S. Fiorucci,et al.  Unveiling hidden features of orphan nuclear receptors: the case of the small heterodimer partner (SHP). , 2006, Journal of molecular graphics & modelling.

[10]  Z. Varga,et al.  Halogen acceptors in hydrogen bonding , 2006 .

[11]  R. Lotan,et al.  Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells , 2005, Molecular Genetics and Genomics.

[12]  R. Xu,et al.  [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. , 2005, Zhonghua yi xue za zhi.

[13]  Janet Hager,et al.  Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP , 2005, Nature Structural &Molecular Biology.

[14]  J. Nicolas,et al.  SHP represses transcriptional activity via recruitment of histone deacetylases. , 2005, Biochemistry.

[15]  F. Zunino,et al.  Cellular and Pharmacological Bases of the Antitumor Activity of a Novel Adamantyl Retinoid, ST1926 , 2004, Journal of chemotherapy.

[16]  A. Rishi,et al.  Antagonist analogue of 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest. , 2004, Journal of medicinal chemistry.

[17]  M. Shong,et al.  Differential role of the loop region between helices H6 and H7 within the orphan nuclear receptors small heterodimer partner and DAX-1. , 2004, Molecular endocrinology.

[18]  Ying Huang,et al.  Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities , 2004, Oncogene.

[19]  R. Mohammad,et al.  Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. , 2003, Blood.

[20]  R. Mohammad,et al.  Identification and Characterization of a Cell Cycle and Apoptosis Regulatory Protein-1 as a Novel Mediator of Apoptosis Signaling by Retinoid CD437* , 2003, Journal of Biological Chemistry.

[21]  E. Erba,et al.  Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. , 2003, Blood.

[22]  P. Mayeux,et al.  Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery? , 2003, Current cancer drug targets.

[23]  G. Giannini,et al.  A novel atypical retinoid endowed with proapoptotic and antitumor activity. , 2003, Journal of medicinal chemistry.

[24]  R. Mohammad,et al.  Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. , 2002, Blood.

[25]  S. Scheiner,et al.  Comparison of various types of hydrogen bonds involving aromatic amino acids. , 2002, Journal of the American Chemical Society.

[26]  J. Gustafsson,et al.  A transcriptional inhibitor targeted by the atypical orphan nuclear receptor SHP , 2002, EMBO reports.

[27]  D. Moras,et al.  Molecular recognition of agonist ligands by RXRs. , 2002, Molecular endocrinology.

[28]  M. Pfahl,et al.  Retinoid-related molecules induce cytochrome c release and apoptosis through activation of c-Jun NH(2)-terminal kinase/p38 mitogen-activated protein kinases. , 2001, Cancer research.

[29]  D. Moras,et al.  Crystal Structure of the Ligand-binding Domain of the Ultraspiracle Protein USP, the Ortholog of Retinoid X Receptors in Insects* , 2001, The Journal of Biological Chemistry.

[30]  R. Evans,et al.  The structure of the ultraspiracle ligand-binding domain reveals a nuclear receptor locked in an inactive conformation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Pettus,et al.  New Construction of Ortho Ring-Alkylated Phenols via Generation and Reaction of Assorted o-Quinone Methides. , 2000 .

[32]  P. Chambon,et al.  Crystal structure of the human RXRα ligand‐binding domain bound to its natural ligand: 9‐cis retinoic acid , 2000 .

[33]  A. Rishi,et al.  Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis , 2000, International journal of cancer.

[34]  V. Nuessler,et al.  Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage , 1999, Leukemia.

[35]  N. Picard,et al.  A selective retinoid with high activity against an androgen‐resistant prostate cancer cell type , 1999, International journal of cancer.

[36]  K. Lempert,et al.  Simple and condensed β-lactams, part 31. Acid catalyzed ring closures and ring transformations of some 3-aryloxy-4-oxoazetidine-2-carbaldehydes , 1998 .

[37]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[38]  D. Moore,et al.  An Orphan Nuclear Hormone Receptor That Lacks a DNA Binding Domain and Heterodimerizes with Other Receptors , 1996, Science.

[39]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[40]  B. Shroot,et al.  Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. , 1995, Journal of medicinal chemistry.

[41]  Norio Miyaura,et al.  Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds , 1995 .

[42]  M. Sheikh,et al.  p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. , 1995, Oncogene.

[43]  D. I. Olifirov,et al.  Reaction of 1-Hydroxyadamantane with Aromatic Amines in the Presence ortho-Alkylation Catalysts. , 1992 .

[44]  G. Chang,et al.  An internal-coordinate Monte Carlo method for searching conformational space , 1989 .

[45]  Yong-soo Lee,et al.  Structure and function of the atypical orphan nuclear receptor small heterodimer partner. , 2007, International review of cytology.

[46]  D. Moore,et al.  Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor. , 2007, Cancer research.

[47]  M. Dawson,et al.  B Activation κ Requires Nuclear Factor-Apoptosis Induction by a Novel Retinoid-Related Molecule , 2005 .

[48]  C. Holzapfel,et al.  STILLE AND SUZUKI CROSS COUPLING REACTIONS OF O-NITROPHENYL TRIFLATES : A VERSATILE ROUTE TO A VARIETY OF HETEROCYCLES , 1998 .

[49]  István Kolossváry,et al.  Low Mode Search . An Efficient , Automated Computational Method for Conformational Analysis : Application to Cyclic and Acyclic Alkanes and Cyclic Peptides , 1997 .

[50]  S. Fornarini,et al.  Gas phase alkylation of dihalobenzenes by free isopropyl cations , 1987 .